Selenium and Haemodialysis: Serum Selenium Levels in Healthy Persons, Non-Cancer and Cancer Patients with Chronic Renal Failure

Kallistratos, G.; Evangelou, A.; Seferiadis, K.; Vezyraki, Patra; Barboutis, K.

doi:10.1159/000183586

Cited by 53 publications

(36 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In Greece the Se concentration in 315 examined foods was shown to be lower than other European countries and closer to UK. The daily Se intake of Greeks is estimated to approximately 110 mg (Kallistratos et al, 1985;Bratakos et al, 1987;Bratakos et al, 1990b;Charalabopoulos et al, 2006).…”

Section: Discussionmentioning

confidence: 99%

“…6 years old, pre-and postmenopausal, were enrolled in the study. A female aged matched population group (consisting of 250 individuals) was selected for comparison of the laboratory data (Kallistratos et al, 1985;Charalabopoulos et al, 2006). In patients, serum Se levels were measured, at the time of diagnosis before any kind of treatment was started, by the fluorometric method (Watkinson's) modified by Thorling.…”

Section: Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA

et al. 2006

View full text Add to dashboard Cite

Trace element selenium (Se) is regarded to be a breast cancer preventive factor involved in multiple protective pathways. In all, 80 women with breast cancer who underwent a radical mastectomy were enrolled in the study. Serum Se and carcinoembryonic antigen levels were measured using a fluorometric and IRMA assay, respectively. Se tissue concentration was determined by a tissue extracting fluorometric assay. For statistical analysis purposes t -test was used and P -values <0.001 were regarded as statistically significant. Serum Se was 42.5±7.5 μ g l −1 in breast cancer patients and 67.6±5.36 μ g l −1 in the age-matched control group of healthy individuals. Serum carcinoembryonic antigen in patients was 10±1.7 U ml −1 (normal <2.5 U ml −1 in nonsmokers/<3.5 U ml −1 in smokers). A statistically significant difference was found for both serum Se and CEA between two groups studied ( P <0.001). Neoplastic tissue Se concentration was 2660±210 mg g −1 tissue; its concentration in the adjacent non-neoplastic tissue was 680±110 mg g −1 tissue ( P <0.001). An inverse relationship between Se and CEA serum levels was found in the two groups studied ( r =−0.794). There was no correlation between serum/tissue Se concentration and stage of the disease. The decrease in serum Se concentration as well as its increased concentration in the neoplastic breast tissue is of great significance. These alterations may reflect part of the defence mechanisms against the carcinogenetic process.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA

et al. 2006

View full text Add to dashboard Cite

show abstract

“…Serum selenium concentrations are generally lower in hemodialysis patients than in healthy controls [29, 30, 31, 32], but very little has been established concerning the mechanisms, including the supposed dialysis-mediated selenium depletion [32]. There is a possibility that the use of polysulfone dialysis membranes leads to loss of selenium through the pores of membranes, but so far there is no direct evidence in the literature supporting this assumption [33].…”

Section: Introductionmentioning

confidence: 99%

Selenium Depletion in Hemodialysis Patients Treated with Polysulfone Membranes

Tompos

Alfthan

2000

Nephron

View full text Add to dashboard Cite

Background/Aims: Epidemiological, animal and human studies have indicated that selenium deficiency is a risk factor for death from malignant diseases. The mechanisms that could modify selenium status may, therefore, be of particular interest in hemodialysis patients, considering their high cancer mortality rates. We aimed at evaluating the effect of hemodialysis with polysulfone membranes on selenium status. Methods: Twenty- eight chronically dialyzed patients and 32 age-matched healthy controls were enrolled in the study. Serum and dialysis fluid selenium concentrations, serum total protein, and hemoglobin concentrations and serum glutathione peroxidase activity were determined before and after the hemodialysis procedure. Results: The (mean ± SD) serum selenium and total protein concentrations and glutathione peroxidase activities were significantly (p < 0.05) higher in healthy controls (75.9 ± 8.3 µg/l, 78 ± 6 g/l, and 23.8 ± 4.8 mU/20 µl, respectively) than in the patients. There was no significant difference between serum selenium concentration before (63.6 ± 11.6 µg/l) and after (64.4 ± 11.4 µg/l) hemodialysis sessions, although hemoglobin and total serum protein concentrations and serum glutathione peroxidase activities increased (from 98.5 ± 1.3 to 114.8 ± 1.5 g/l, from 64 ± 8 to 71 ± 9 g/l, and from 16.8 ± 1.8 to 18.9 ± 1.9 mU/20 µl, respectively) significantly (p < 0.05) during hemodialysis, indicating hemoconcentration. The selenium concentration doubled, and protein appeared in the dialysates during dialysis session. The correlation of the selenium concentrations with the protein concentrations in the dialysate is significant (p < 0.01) with a Spearman R value of 0.97. Conclusion: The results of the present study suggest that selenium is lost through the pores of polysulfone membranes during hemodialysis which is associated with their protein permeability.

show abstract

“…Számos vizsgálatban kimutatták, hogy hemodializált betegekben a szelén koncentrációja csökkent az egész-ségesekhez képest, és ez alapja lehet a fokozott cardiovascularis kockázatnak és a nagyobb mortalitásnak is [21,22,23,24,25]. Folyamatos ambuláns peritonealis dialízissel (CAPD) kezelt vesebetegekben alacsonyabb szelénszintet találtak, mint hemodializált betegekben [22].…”

Section: Szelénmetabolizmus Krónikus Vesebetegségbenunclassified

“…Dializált betegekben csökkent a szérum, a vörösvértest és fehér-vérsejt szeléntartalma [32,33,34], bár normális szé-rumszintet is kimutattak dializált betegekben [20,26]. A szelénszint csökkenése oka lehet a kialakuló congestiv cardiomyopathiának, az akcelerált atherosclerosisnak, a vázizomzat myopathiájának, az anaemiának, a fokozott tumorkockázatnak, az arthritisnek, a termé-ketlenségnek, a cataracta kialakulásának, a kognitív diszfunkciónak és a károsodott immunfunkciónak krónikus vesebetegségben, illetve veseelégtelenségben szenvedő betegekben [21,26,28,34,35,36,37,38].…”

Section: Szelénmetabolizmus Krónikus Vesebetegségbenunclassified

Importance of selenium homeostasis in chronic and end-stage kidney diseases

Kiss

2013

Orvosi Hetilap

View full text Add to dashboard Cite

A szelén az emberi szervezet számára nélkülözhetetlen nyomelem, jelentős antioxidáns hatással rendelkezik. A szelénhiány és -többlet egyaránt károsan befolyásolja a szervezet működését. A szelénhiány és az akut vagy krónikus vesebetegség, illetve a szövődmények kapcsolata kevésbé intenzíven kutatott terület. Az eddigi eredmények alapján ismertté vált, hogy a szelénhiány és a veseelégtelenség fokozza a koszorúér-betegség okozta és az összhalálozás kockázatát. További megfi gyelések szerint a szelénhiány az immunrendszer működési zavarán keresztül fokozza az infekció okozta halálozás kockázatát hemodializált betegekben. Jelenleg azonban nincs tudomásunk arról, hogy a szelén-háztartás zavara, elsősorban a szelén hiánya, krónikus vesebetegséget vagy veseelégtelenséget okozna. Ugyanakkor elégséges ismerettel rendelkezünk arról, hogy a fehérjevesztés és a vesepótló kezelés csökkentheti a szelénszintet. A szelénhiány és a krónikus vesebetegség kapcsolatával foglalkozó vizsgálatok gyakran ellentmondó eredményei ellenére úgy tűnik, hogy súlyos vagy végállapotú, vesepótló kezelésre szoruló dializált betegekben a szelénszupplemen-táció számos esetben kedvező lehet. Orv. Hetil., 2013, 154, 1641-1647. Kulcsszavak: szelénhiány, cardiovascularis kockázat, krónikus vesebetegség, vesepótló kezelés Importance of selenium homeostasis in chronic and end-stage kidney diseasesSelenium is an essential trace element for the human body with a signifi cant antioxidant effect. Selenium defi ciency and excess are both detrimental for proper functioning of the human body. The possible association between selenium defi ciency and acute or chronic renal disease, along with their complications has been less intensively investigated, however, there are fi rm data showing that selenium defi ciency and renal failure increase the risk of both coronary artery disease and total mortality. Further studies revealed that selenium defi ciency increases the risk of death due to infection in patients treated with hemodialysis through dysfunction of the immune system. However, there are no data whether the imbalance of selenium metabolism, especially selenium defi ciency, could cause chronic kidney disease or renal failure. As far as results of selenium measurements, there is convincing evidence that protein loss and renal replacement treatment reduce serum selenium levels. Despite some contradictory results obtained from various studies regarding selenium defi ciency in chronic kidney diseases, it seems that selenium supplementation may be benefi cial in many patients with severe or end-stage kidney disease including those treated with dialysis.Keywords: selenium defi ciency, cardiovascular risk, chronic renal disease, hemodialysis Kiss, I. (2013)

show abstract

Selenium and Haemodialysis: Serum Selenium Levels in Healthy Persons, Non-Cancer and Cancer Patients with Chronic Renal Failure

Cited by 53 publications

References 16 publications

Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA

Selenium in serum and neoplastic tissue in breast cancer: correlation with CEA

Selenium Depletion in Hemodialysis Patients Treated with Polysulfone Membranes

Importance of selenium homeostasis in chronic and end-stage kidney diseases

Contact Info

Product

Resources

About